吉西他滨联合顺铂或卡培他滨治疗耐药的晚期乳腺癌的临床价值  

Clinical value of gemcitabine plus cisplatin or capecitabine in the treatment of resistant advanced breast cancer

作　　者：雷俊华[1] 洪涛[1] 曾江正[1] 黄芬[1] 何志惠[1] 苏群豪[1] 

机构地区：[1]海南医学院附属医院肿瘤内科,海南海口570102

出　　处：《海南医学》2013年第15期2197-2199,共3页Hainan Medical Journal

摘　　要：目的观察吉西他滨联合顺铂或卡培他滨治疗对蒽环类和紫杉类耐药的复发转移性晚期乳腺癌的疗效及不良反应。方法我院2008年8月至2012年10月期间收治因蒽环和紫杉类药物治疗失败的患者共48例，将其分为GP组和GX组，每组24例，两组临床资料差异无统计学意义。GP组：吉西他滨1000mg／m^2，d1、8，顺铂25mg／m^2d1-3，21d为一个周期；GX组：吉西他滨1000mg／m^2，d1、8，卡培他滨2000mg／m^2d1-14，21d为一个周期。吉西他滨静滴30min，卡培他滨分两次餐后30min温开水送服。结果GP组患者的CR0例，PR8例，SD11例，PD5例，有效率为33．3％（8／24）。GX组患者的CR1例，PR9例，sD9例，PD5例，有效率为41．7％（10／24），其差异无统计学意义（P〉0．05）。主要不良反应为骨髓抑制、消化道反应。结论吉西他滨为主的两药联合方案对蒽环类和紫杉类耐药的复发转移乳腺癌有较好的疗效，不良反应可耐受，是临床值得推荐的治疗方案。Objective To evaluate the efficacy and toxicity of gemcitabine plus cisplatin or capecitabine in the treatment of patients with metastatic breast cancer previously treated with anthracycline and taxane-resistant. Methods Forty-eight patients failed in anthracycline and taxane treatment in our hospital from August 2008 to Octo- ber 2012 in our hospital were divided into two groups： group GP and group GX, with 24 cases in each group. The two groups showed no statistically significant difference in clinical characteristics, GP group： gemcitabine （I 000 mg/m2） dl, 8 and cisplatin （25 mg/m2） on dl-3, every 21 days was one cycle. GX group： gemcitabine （1 000 mg/m2） dl and d8 and Capecitabine 2 000 mg/m2 dl-14, every 21 days was one cycle. Results GP group： 0 case of CR, 8 cases of PR, 11 cases of SD and 5 cases of PD. The total effective rate was 33.3%, GX group： 1 case ofCR, 9 cases ofPR, 9 cases of SD and 5 cases of PD. The total effective rate was 41.7%. No statistically significant difference was observed between two groups （P〉0.05）. The main adverse reaction included myelosuppression and gastrointestinal reaction. Conclusion Gemcitabine combinsd with cisplatin or capecitabine is well tolerated and active with metastatic breast cancer oreviousl7 treated with anthracvcline and taxane-resistant.

关 键 词：晚期乳腺癌 吉西他滨 联合化疗 

分 类 号：R737.9[医药卫生—肿瘤]